Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13563786 | 0.87 | KDM4E (0.47) | KDM4EMAPTALDH1A1HSD17B10GAA | |
| SCHEMBL4076913 | 0.85 | ALDH1A1 (0.41) | KDM4EMAPTALDH1A1HSD17B10GAA | |
| SCHEMBL6883767 | 0.83 | TSHR (0.55) | KDM4EMAPTALDH1A1HSD17B10GAA | |
| SCHEMBL22852764 | 0.82 | TSHR (0.46) | KDM4EMAPTALDH1A1HSD17B10GAA | |
| SCHEMBL30294289 | 0.82 | TSHR (0.46) | KDM4EMAPTALDH1A1HSD17B10GAA | |
| SCHEMBL286232 | 0.82 | CA12 (0.49) | KDM4EMAPTALDH1A1HSD17B10GAA | |
| SCHEMBL4178450 | 0.81 | CA12 (0.47) | KDM4EMAPTALDH1A1HSD17B10GAA | |
| SCHEMBL13870603 | 0.80 | CYP4F2 (0.51) | KDM4EMAPTALDH1A1HSD17B10GAA | |
| SCHEMBL7992182 | 0.79 | CYP4F2 (0.48) | KDM4EMAPTALDH1A1HSD17B10GAA | |
| SCHEMBL22852763 | 0.79 | TSHR (0.46) | KDM4EMAPTALDH1A1HSD17B10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383908-A1 | SYNTHESIS AND APPLICATION OF PHOSPHATASE DEGRADER | HINOVA PHARMACEUTICALS INC. (CN) | 2024-11-21 | — | — | US | disclosed |
| CN-115594666-B | Synthesis and application of phosphatase degradation agent | 海创药业股份有限公司 | 2024-05-31 | — | — | CN | disclosed |
| EP-4368614-A1 | SYNTHESIS AND APPLICATION OF PHOSPHATASE DEGRADER | Hinova Pharmaceuticals Inc. (CN) | 2024-05-15 | — | — | EP | disclosed |
| CN-115594666-A | Synthesis and application of phosphatase degrading agent | 海创药业股份有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| WO-2023280237-A1 | SYNTHESIS AND APPLICATION OF PHOSPHATASE DEGRADER | 海创药业股份有限公司 | 2023-01-12 | — | — | WO | disclosed |
| WO-2023280237-A1 | SYNTHESIS AND APPLICATION OF PHOSPHATASE DEGRADER | 海创药业股份有限公司 | 2023-01-12 | — | — | WO | disclosed |
| EP-2064545-B1 | METHOD FOR IDENTIFYING COMPOUNDS THAT ACT AS INSULIN-SENSITIZERS | PIRAMAL LIFE SCIENCES LTD (IN) | 2012-07-04 | — | — | EP | disclosed |
| US-7964628-B2 | Fibrinogen receptor antagonists and their use | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-06-21 | — | — | US | disclosed |
| EP-2256496-A2 | Method for identifying compounds that act as insulin-sensitizers | Piramal Life Sciences Limited (IN) | 2010-12-01 | — | — | EP | disclosed |
| US-20100256161-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-10-07 | — | — | US | disclosed |
| US-7759387-B2 | Fibrinogen receptor antagonists and their use | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-07-20 | — | — | US | disclosed |
| US-20090318465-A1 | METHOD FOR IDENTIFYING COMPOUNDS THAT ACT AS INSULIN-SENSITIZERS | Piramal Enterprises Limited (IN) | 2009-12-24 | — | — | US | disclosed |
| EP-2064545-A2 | METHOD FOR IDENTIFYING COMPOUNDS THAT ACT AS INSULIN-SENSITIZERS | Piramal Life Sciences Limited (IN) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008035309-A2 | METHOD FOR IDENTIFYING COMPOUNDS THAT ACT AS INSULIN-SENSITIZERS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2008-03-27 | — | — | WO | disclosed |
| US-20070021489-A1 | Fibrinogen receptor antagonists and their use | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2007-01-25 | — | — | US | disclosed |
| EP-1677783-A2 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | Nicholas Piramal India Limited (IN) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005035495-A2 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256161-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | FGB, F13B, F2 | KDM4E 4730/4885MAPT 4727/4885ALDH1A1 2548/4885 |
| US-20070021489-A1 | Fibrinogen receptor antagonists and their use | FGB, F13B, F2 | KDM4E 4730/4885MAPT 4727/4885ALDH1A1 2548/4885 |
| US-20240383908-A1 | SYNTHESIS AND APPLICATION OF PHOSPHATASE DEGRADER | DUSP1, PPM1D, PTPN1 | KDM4E 613/4885MAPT 3181/4885ALDH1A1 1769/4885 |
| US-20090318465-A1 | METHOD FOR IDENTIFYING COMPOUNDS THAT ACT AS INSULIN-SENSITIZERS | GPR119, SLC2A4, INSR | KDM4E 3621/4885MAPT 2776/4885ALDH1A1 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.